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INTRODUCTION

▪COVID-19 is a disease caused by a novel Coronavirus (SARS-CoV-2)
originating in Wuhan, China around December 2019. On March 11, 2020 it
was declared a pandemic by the World Health Organization (WHO) as the
number of infections rapidly grew around the world. Currently, cases have
described COVID-19 involvement in respiratory, gastrointestinal,
neurological, and ocular tissues. Respiratory droplets and direct contact are
the most probable transmission routes, although aerosolized sneezes and
coughs may also contaminate the immediate surroundings.[1]
▪COVID-19 most commonly causes respiratory symptoms such as dyspnea
and cough which may progress to pneumonia and ARDS in a subset of
patients, however recent studies have demonstrated neurological
manifestations such as dizziness, headache, hypogeusia, hyposmia,
neuralgia, impaired consciousness, acute CVD, ataxia, and seizure.[2][3]
SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor
in human cells which is hypothesized to allow CNS access by ACE2 receptor
expressing glial cells, neurons, endothelial and arterial smooth muscle cells
in the brain.[4] A recent case of meningitis/encephalitis with SARS-CoV-2
RNA detected in the CSF directly supports the neuroinvasive ability of the
virus.[5] In addition, SARS-CoV-2 has a similar viral structure and receptorbinding domain to SARS-CoV, a more well studied virus that demonstrated
olfactory bulb infection with transneuronal spread in mice leading to
neuronal loss.[4] Considering these characteristics, it is reasonable to
conclude that SARS-CoV-2 shows neurotropism that can manifest
neurological symptoms in an infected individual.
▪Recently, there have been case reports of neuro-ophthalmological
manifestations in association with COVID-19 such as diplopia, Miller-Fisher
syndrome, ophthalmoplegia, and polyneuritis cranialis. There is currently a
limited number of publications that have been able to elaborate the
neurological impact of COVID-19 on ocular tissues. To the best of our
knowledge this is the first case describing acute strabismus decompensation
following COVID-19 infection.
CASE PRESENTATION

A 27-year-old female presents to the emergency room with acute onset
horizontal binocular diplopia and a history of COVID-19 infection 1-2
weeks prior. She has a history of longstanding intermittent right esotropia,
myopia, and well-treated amblyopia in the right eye with excellent best
corrected visual acuity. She states that before her COVID-19 infection she
only had double vision after extended reading and typically sees clearly.
Now she has constant double vision which started acutely earlier that day
and worsened over the several hours. Her only other symptom at the time
was increased fatigue. She was afebrile and denies having any respiratory
or GI symptoms. During examination of eye tracking, there was a left
esotropia when looking left and a right esotropia when looking right. Labs
showed a normal WBC count, C-Reactive Protein, and ESR. The CT
angiogram of the head with and without contrast, chest X-ray, and MRI of
brain without contrast showed no abnormalities.

CASE PRESENTATION (cont.)

She was discharged with a Medrol Dosepak for 6th nerve palsy with follow
up as needed. Around 3 weeks later, she presented to the optometrist
with horizontal diplopia. She states the diplopia has been stable and
constant since her visit to the emergency department 3 weeks prior. On
physical examination, her visual acuity was 20/20 in both eyes with a
corrective lens. Motility was full to ductions and versions. An alternating
esotropia greater than 45 prism diopters was found with the coveruncover test. Confrontational visual fields were full to count fingers. Pupils
were equal, round, and reactive to light with no afferent pupillary defect.
Intraocular eye pressure was measured to be 18 mmHg in both eyes via
Goldmann tonometry. Slit lamp and dilated fundoscopic exam was
unremarkable. She was diagnosed with alternating esotropia after
decompensation of an intermittent esotropia in the right eye. Three weeks
later during follow up, she reports a gradual and small improvement of the
diplopia in her near vision. Her distance vision, however, is still perceived
to be doubled with little to no improvement.
RESULTS & DISCUSSION

▪The present case illustrates an acute strabismus decompensation as a
neurological manifestation of COVID-19 infection. Based on our scientific
literature review, this is the first reported case of decompensated
strabismus as a direct result of COVID-19 infection.
▪Strabismus is an anomaly of ocular alignment found in 2-4% of the
population and is responsible for complications such as diplopia and
amblyopia. Many cases are congenital; however, instances of acute
strabismus may be seen in association with viral infections.
▪There are few studies on the spectrum of neuro-ophthalmologic
manifestations that occur in association with COVID-19. Consuelo
Gutiérrez-Ortiz et al. presented 2 cases of COVID-19, one with Miller-fisher
syndrome and another with polyneuritis cranialis. The author hypothesized
that these manifestations may be due to an aberrant immune response to
COVID-19.[7] Marc Dinkin et al. described 2 cases of COVID-19 after
presenting with diplopia and ophthalmoparesis.[6] It was hypothesized in
one case to be a direct neurological infection, because there were
neurologic manifestations within a few days of COVID-19 onset. In both
cases, it was stated that acute cranial neuropathy should prompt
consideration for COVID-19.[6][7] Overall, these publications may share
similarities to our case with respect to the possible pathophysiological
pathway, though the exact mechanism has yet to be thoroughly explored.
▪SARS-CoV-2 is an emerging strain of virus causing infections on a
pandemic scale. Its neurological effects are poorly understood and may
have a long-term impact that signifies a burden to the patient and the
health care system. Understanding the neurological manifestations on
ocular tissues may help in the recognition and diagnosis of the disease
while promoting the need for targeted therapeutics. Further studies are
needed to understand the pathogenesis of neurological manifestations
due to COVID-19.

CONCLUSION

COVID-19 has neurotropic effects which can result in decompensation
for patients with strabismus. Understanding the neurological
manifestations of the disease may help in the recognition and
diagnosis while promoting the need for targeted therapeutics. This is
the first reported case we are aware of with decompensated
strabismus due to COVID-19.
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